Report | Question ID | Question | Discussion | Answer | Year |
---|---|---|---|---|---|
|
20061009 | CS Site Specific Factor--Breast: If there are two ER/PR tests, one positive and one negative, which result should be coded in the SSF fields 1 and 2? See Discussion. | SINQ #20021074 states that for cases up to 2003, if there are differences in ER/PR results, to code the positive findings over the negative findings. Does this hold true for coding SSF1 & SSF2 for breast? Scenario: 10/19 Breast bx: ER + PR -; No date/specimen: ER/PR -; 12/3 Partial Mast: ER/PR + |
This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2. For cases diagnosed prior to January 1, 2007, according to the CS Steering Committee, record the pathologist's interpretation of the assay value for the most representative tumor specimen. This may require conversation with the pathologist when specimen size is not specified. |
2006 |
|
20061008 | Histology (Pre-2007)--Corpus uteri: How is a polyp with "endometrial carcinosarcoma (Malignant Mixed Mullerian tumor), endometrial adenocarcinoma, and some areas of high grade spindle sarcoma" coded? See Discussion. | The path report for the TAH stated the endometrium contained an endometrial polyp measuring 6x3x3cm. Within the polyp there was endometrial carcinosarcoma (Malignant Mixed Mullerian tumor), endometrial adenocarcinoma, and some areas of high grade spindle sarcoma. There is no myometrial invasion by the tumor. (The Endometrial bx before surgery was positive for Malignant Mixed Mullerian tumor.) | For tumors diagnosed prior to 2007:
Assign code 8980 [Carcinosarcoma, NOS]. According to the WHO Classification of tumors, Malignant mullerian mixed tumor is a synonym for carcinosarcoma and carcinosarcoma is now the preferred terminology rather than malignant mixed Mullerian tumor. Carcinosarcoma has both malignant epithelial and mesenchymal components. The epithelial component is usually glandular (adenocarcinoma in this case). The mesenchymal component is usually sarcoma (as in this case).
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
2006 |
|
20061006 | Multiple Primaries (Pre-2007)/Histology (Pre-2007)--Testis: If an orchiectomy specimen contains non-seminomatous mixed germ cell tumor and a separate satellite of seminoma, how many tumors should be abstracted and how should the histology field(s) be coded? | Pathology: R Orchiectomy: 2.1 cm non-seminomatous mixed germ cell tumor (50% teratoma primarily mature, 50% embryonal CA and yolk sac tumor). Located 3cm from the main tumor is a 2mm satellite pure seminoma. | For tumors diagnosed prior to 2007:
This is a single primary because the first three digits of the ICD-O-3 histology codes are the same, according to Rule 3a on page 11 of the 2004 SEER manual. Code the histology 9065 [Germ cell tumor, nonseminomatous]. Code 9065 is preferred over the less-specific code of 9061 [Seminoma, NOS].
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
2006 |
|
20061005 | CS Reg LN Pos/Exam: Are lymph nodes coded as positive or negative when the pathology report for a lymph node dissection performed after radiation and chemo reveals that the nodes are negative but they demonstrated previous involvement by cancer? See Discussion. | Scenario: The patient was treated with radiation and chemotherapy prior to resection for esophageal cancer. The pathology report stated, "1/3 nodes c/w treated previous ca." | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.Record lymph nodes that are pathologically confirmed as positive in Regional Nodes Positive. Evidence of previous involvement by cancer is not recorded in this data item. In the above scenario, the lymph nodes are negative according to pathology. Clinically positive lymph nodes are coded in CS Lymph Nodes. |
2006 |
|
20061004 | CS Site Specific Factor--Breast: If the tumor is described as being a 1 cm poorly differentiated pleomorphic lobular carcinoma with scattered LCIS in breast tissue, for SSF6, do we use the breast tumor or all of the breast tissue removed when coding SSF6? |
This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2. Site Specific Factor 6 in the breast scheme describes the relationship of invasive and in situ tumor in the tumor size coded. Code SSF6 for the same tumor used to code tumor size. For this example, code SSF6 for the 1 cm tumor. In this case, the entire tumor is reported as invasive; use code 000 [Entire tumor reported as invasive]. |
2006 | |
|
20061003 | Reportability--Brain and CNS: Is Langerhans cell histiocytosis [9751/1] of the meninges [C709] reportable? | For cases diagnosed prior to 1/1/2010:Yes. The criteria for reportable benign/borderline CNS tumors is based on location (site) and behavior (benign/borderline). There is no caveat for histologic type. Therefore, this would be reportable as these tumors have been reported arising from the meninges or choroid plexus. For cases diagnosed 2010 forward, refer to the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database (Hematopoietic DB) provided by SEER on its website to research your question. If those resources do not adequately address your issue, submit a new question to SINQ. |
2006 | |
|
20061002 | Multiple Primaries (Pre-2007): How many primaries? See Discussion. | 5/05 perianal skin bx, 6/05 mapping bx perianal skin, 9/05 punch bx perianal skin: all positive for extramammary Paget Disease. 9/05 Perianal Excision of Paget w/V-Y flap repair. Path: Perianal and anal skin: Extramammary Paget disease associated with: Invasive adenoca of anal canal. Anal margins positive for invasive adenoca. Comment: invasive adenoca with local mucinous features involving the anal margin/end of specimen. This adenoca is in continuity with (associated with) extensively diffuse extramammary Paget disease. Unclear whether the adenoca represents a rectal primary with spread to perianal area, anal gland adenoca or mets. 12/05 AP resection-no residual Paget or invasive neoplasm. | For tumors diagnosed prior to 2007:
There is one primary. Code the histology to 8542 [Paget disease, extramammary]. Code the primary site C210 [anus]. Histology rule 7 on page 87 of the 2004 SPCM applies in this case.
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
2006 |
|
20061001 | 2004 SEER Manual Errata/CS Lymph Nodes--Head & Neck: On page C-353, in the supraglottic larynx schema, there is no mention of Level IV nodes in the CS Lymph Node codes. | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.The CS Steering Committee is aware of this issue and is working to resolve it. |
2006 | |
|
20051145 | CS Extension/CS Mets at Dx--Colon: How is a small focus of metastatic disease in the submucosa coded for a sigmoid primary? See Discussion. |
Path final diagnosis states: "No lymph node metastases identified. One submucosal met in a block taken from a surgical margin section." Path micro states: "Microscopic involvement of the border between the serosa and muscularis propria. Sections of proximal & distal surgical margins reveal no tumor in one, and a small focus of metastatic disease in the submucosa of the other. This focus of tumor exists in a small vascular channel and is complete in and of itself; ie, it has not been cut thru by excision of the specimen from the patient." |
This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2. This submucosal metastasis does not affect CS extension. It is not part of CS or TNM staging. According to the TNM supplement, "Multiple tumour foci in the mucosa or submucosa ("skip metastasis") are not part of the TNM classification and should not be classified as distant metastasis. |
2005 |
|
20051144 | CS Lymph Nodes: Are lymphatic channels/vessels within an organ coded as regional lymph nodes? | This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.Lymphatic channels/vessels carry lymph fluid throughout the organs and tissues of the body. Lymph channels/vessels within an organ are not nodes. Lymph channels/vessels outside an organ are not nodes. |
2005 |